ATE412657T1 - Therapeutische quinazolin-derivate - Google Patents

Therapeutische quinazolin-derivate

Info

Publication number
ATE412657T1
ATE412657T1 AT03789562T AT03789562T ATE412657T1 AT E412657 T1 ATE412657 T1 AT E412657T1 AT 03789562 T AT03789562 T AT 03789562T AT 03789562 T AT03789562 T AT 03789562T AT E412657 T1 ATE412657 T1 AT E412657T1
Authority
AT
Austria
Prior art keywords
quinazoline derivatives
therapeutic
therapy
processes
formula
Prior art date
Application number
AT03789562T
Other languages
English (en)
Inventor
Andrew Mortlock
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE412657T1 publication Critical patent/ATE412657T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03789562T 2002-12-24 2003-12-22 Therapeutische quinazolin-derivate ATE412657T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02293240 2002-12-24

Publications (1)

Publication Number Publication Date
ATE412657T1 true ATE412657T1 (de) 2008-11-15

Family

ID=32668917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03789562T ATE412657T1 (de) 2002-12-24 2003-12-22 Therapeutische quinazolin-derivate

Country Status (8)

Country Link
US (1) US20060058325A1 (de)
EP (1) EP1575966B1 (de)
JP (1) JP2006512387A (de)
AT (1) ATE412657T1 (de)
AU (1) AU2003294142A1 (de)
DE (1) DE60324461D1 (de)
ES (1) ES2314271T3 (de)
WO (1) WO2004058782A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050087863A (ko) * 2002-12-24 2005-08-31 아스트라제네카 아베 퀴나졸린 화합물
RU2005135337A (ru) 2003-04-16 2006-06-10 Астразенека Аб (Se) Производные хиназолина для лечения злокачественного новообразования
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
CA2581516C (en) 2004-10-12 2013-06-11 Astrazeneca Ab Quinazoline derivatives
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
EA019879B1 (ru) 2005-12-29 2014-07-30 Лексикон Фармасьютикалз, Инк. Полициклические производные аминокислот, содержащая их фармацевтическая композиция и способ лечения, использующий эти производные
JP5161072B2 (ja) * 2006-04-27 2013-03-13 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
CA2740746A1 (en) * 2008-10-14 2010-04-22 Ning Xi Compounds comprising a spiro-ring and and methods of use
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN103304489B (zh) * 2012-03-16 2015-03-11 中国农业科学院兰州畜牧与兽药研究所 嘧啶苯甲酰胺类化合物及其制备和应用
CA2900652C (en) 2013-02-15 2021-05-04 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN107915751A (zh) 2013-02-20 2018-04-17 卡拉制药公司 治疗性化合物和其用途
WO2015066482A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX2019002629A (es) 2016-09-08 2019-10-07 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapéuticos y usos de los mismos.
AU2017324716B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
JP2003509497A (ja) * 1999-09-21 2003-03-11 アストラゼネカ アクチボラグ キナゾリン化合物とそれらを含有する医薬組成物
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
US20030064119A1 (en) * 2001-06-21 2003-04-03 Emerson Ralph W. Methods and compositions for applying essential oils and naturally occurring compounds to plants to activate endogenous plant pathogen defense pathways

Also Published As

Publication number Publication date
EP1575966B1 (de) 2008-10-29
DE60324461D1 (de) 2008-12-11
JP2006512387A (ja) 2006-04-13
WO2004058782A1 (en) 2004-07-15
AU2003294142A1 (en) 2004-07-22
US20060058325A1 (en) 2006-03-16
ES2314271T3 (es) 2009-03-16
EP1575966A1 (de) 2005-09-21

Similar Documents

Publication Publication Date Title
DE60324461D1 (de) Therapeutische quinazolin-derivate
MY136174A (en) Phosphonooxy quinazoline derivatives and their pharmaceutical use
MXPA05006920A (es) Compuestos de quinazolina.
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
NO20051695L (no) Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer
SE0101387D0 (sv) Novel compounds
DE60328010D1 (de) Heterocyclische verbindungen
SE9904505D0 (sv) Novel compounds
SE0202463D0 (sv) Novel compounds
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
ATE302775T1 (de) Carbolinderivate
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
DE60121461D1 (de) Kondensierte pyridoindolderivate
ATE346067T1 (de) Carbolinderivate
GB0308201D0 (en) Novel compounds
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
DE60013486D1 (de) Verbindungen
DE60305053D1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
UA86470C2 (ru) Производные фосфонооксихиназолина и их фармацевтическое применение
DK1789044T3 (da) Phenylaminopyridiner og phenylaminopyraziner
ATE343576T1 (de) 7-azaindolderivate als cox2-inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties